Safety and pharmacokinetics of BAY 1817080, a P2X3 receptor antagonist, in healthy subjects: Results from a double-blind, randomised study

被引：0
|
作者：
Friedrich, Christian [1 ]
Francke, Klaus [1 ]
Gashaw, Isabella [1 ]
Scheerans, Christian [1 ]
Klein, Stefan [1 ]
Fels, Lueder [1 ]
Smith, Jaclyn [2 ,3 ]
Hummel, Thomas [4 ]
Morice, Alyn [5 ]
机构：
[1] Bayer AG, Leverkusen, Germany
[2] Univ Manchester, Immun & Resp Med, Manchester, Lancs, England
[3] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[4] Tech Univ Dresden, Dept Otorhinolaryngol, Smell & Taste Clin, Dresden, Germany
[5] Univ Hull, Resp Res Grp, Hull York Med Sch, Kingston Upon Hull, N Humberside, England
来源：
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2021年 / 87卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P132
引用
收藏
页码：1614 / 1616
页数：3
相关论文
共 50 条
  • [41] First-in-human safety, tolerability, and pharmacokinetics of ammoxetine in healthy subjects: a randomized, double-blind, placebo-controlled phase I study
    Shen, Qi
    Hu, Chao
    Miao, Jia
    Chen, Junxia
    Peng, Yueying
    Pan, Tingting
    He, Xiaolin
    Yuan, Jing
    Ni, Shaonan
    Wang, Yongsheng
    Luo, Zhu
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 159
  • [42] A phase I randomized, double-blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
    Gu, Kenan
    Ruff, Dennis
    Key, Cassandra
    Thompson, Marissa
    Jiang, Shoshanna
    Sandison, Taylor
    Flanagan, Shawn
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2022, 15 (07): : 1592 - 1598
  • [43] Safety, tolerability and pharmacokinetics of WXFL10203614 in healthy Chinese subjects: A randomized, double-blind, placebo-controlled phase I study
    Huang, Kai
    Ding, Ying
    Que, Linling
    Chu, Nannan
    Shi, Yunfei
    Qian, Zhenzhong
    Qin, Wei
    Chen, Yuanxin
    Gu, Xianghong
    Wang, Jiakun
    Zhang, Zhiwei
    Xu, Jianguo
    He, Qing
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [44] Coadministration of mirogabalin and ethanol in healthy subjects: Results from a randomized, double-blind, drug-drug interaction study
    Jansen, M.
    Merante, D.
    Currie, A.
    Velinova, M.
    Zahir, H.
    JOURNAL OF PAIN, 2015, 16 (04): : S73 - S73
  • [45] Pharmacokinetic Similarity of ABP 654, an Ustekinumab Biosimilar Candidate: Results from a Randomized, Double-blind Study in Healthy Subjects
    Chow, Vincent
    Mytych, Daniel T.
    Das, Shyamal
    Franklin, Janet
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2023, 12 (09): : 863 - 873
  • [46] Safety and pharmacokinetics of the nonnucleoside polymerase inhibitor, HCV-796: Results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects
    Chandra, P.
    Raible, D.
    Moyer, L.
    Harper, D.
    Speth, J.
    Villano, S.
    Fruncillo, R.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S208 - S209
  • [47] A First-In-Human, Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Ketamine in Healthy Volunteers
    Silman, Daniel
    Gadelrab, Romayne
    Qureshi, Mutahira
    Stein, Hans
    Mehta, Mitul
    Carmelline, Pietro
    Young, Allan
    Reilly, Carmel
    Duncan, Graeme
    Juruena, Mario
    NEUROPSYCHOPHARMACOLOGY, 2024, 49 : 155 - 155
  • [48] Safety, Tolerability and Pharmacokinetics of FAAH Inhibitor V158866: A Double-Blind, Randomised, Placebo-Controlled Phase I Study in Healthy Volunteers
    Pawsey S.
    Wood M.
    Browne H.
    Donaldson K.
    Christie M.
    Warrington S.
    Drugs in R&D, 2016, 16 (2) : 181 - 191
  • [49] Phase 2a Randomized, Double-Blind, Placebo-Controlled, Crossover Study of a P2x3 Receptor Antagonist S-600918: Effects on Health-Related Quality of Life in Patients with Refractory Chronic Cough
    Niimi, A.
    Ishihara, H.
    Hida, H.
    Miyazaki, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [50] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study
    Haiyan Li
    Yudong Wei
    Zhenhua Yang
    Shuang Zhang
    Xiuxiu Xu
    Mengmeng Shuai
    Olivier Vitse
    Yiwen Wu
    Marie T. Baccara-Dinet
    Yi Zhang
    Jianyong Li
    American Journal of Cardiovascular Drugs, 2020, 20 : 489 - 503
12345